AstraZeneca CEO doubles down on U.S. amid rumors of listing shift

Nurphoto | Getty ImagesAstraZeneca CEO Pascal Soriot on Tuesday reiterated the pharmaceutical firm's commitment to the U

Market amid reports that he is considering shifting its listing stateside, considering recent developments

Moreover, Additionally, -listed company had many reasons to be in the U. , adding that it was "rapidly transferring manufacturing" across the Atlantic so it could serve all U, in today's market environment

Patient needs domestically. "We have lots of reasons to be here [in the U. ]," Soriot told media during an earnings call

On the other hand, "This country [the U. ] will represent, we hope, 50% of our revenue by 2030

At the same time, We have thousands of employees … across the country," he added

AstraZeneca has been doubling down on the U (noteworthy indeed), amid market uncertainty

Conversely, "We're a global company but we are certainly, very much, present and rooted in the U

On the other hand, ," Soriot said, noting that it plans to soon become self-sufficient there

Moreover, The company said last week it plans to invest $50 billion in bolstering its U

However, Manufacturing and re capabilities

It marks the pharmaceutical firm to ramp up its stateside spending in the wake of U

Trade tariffs and calls by President Donald Trump to reshore manufacturing (this bears monitoring) (which is quite significant). "Our investment is reflecting our belief in the growth of this country

We want to contribute to this," Soriot said, noting that he had met with the Trump administration to discuss growth plans within the sector

Really leads in biopharmaceutical innovation these days," he added, criticizing Europe's failure to drive development (which is quite significant), amid market uncertainty. "Today, very little comes out of Europe

Moreover, "A shift stateside

AstraZeneca, which made international headlines by one of the key Covid-19 vaccines, has long been prioritizing the U (noteworthy indeed)

Nevertheless, Earlier this month, The Times reported that the firm may move its listing from London to the U. , in what analysts said would be a major blow to the U

Furthermore, AstraZeneca at the time declined to on the report

However, chief financial officer Aradhana Sarin said Tuesday that the company remains "committed" to the U

It comes as AstraZeneca posted better-than-expected second-quarter earnings on Tuesday, driven by demand for key cancer and biopharmaceutical ducts, given the current landscape

As part of a broader EU-U

Additionally, Trade deal, given the current landscape

Furthermore, However, Tariffs on European pharma ducts came in in line with those levied against other sectors

On the other hand, "This issue of tariffs is not really an issue that is affecting us very much," Soriot said.